HIV

HIV Self-Testing Increases Testing Frequency in High-Risk MSM

HIV Self-Testing Increases Testing Frequency in High-Risk MSM

By

Research is needed to understand how to prioritize supplementation and reach new testers, to educate men about the limitations of the current self-test, and to invest in the development and evaluation of self-tests able to detect early infection.

Fungal Infections of the CNS: Diagnostic and Treatment Approaches

Fungal Infections of the CNS: Diagnostic and Treatment Approaches

By

While immunocompromised patients are the most susceptible to CNS fungal infections, they can also occur in immunocompetent patients undergoing invasive procedures such as neurosurgery and in patients exposed to contaminated devices or drugs.

Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

By

Standard-dose efavirenz-based short cycle therapy is a viable option for virologically suppressed HIV-1-infected young people receiving first-line antiretroviral therapy with 3-monthly viral load monitoring.

FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents

FDA: Possible Risk of Neural Tube Birth Defects With Certain Antiretroviral Agents

By

The FDA has received reports of serious neural tube birth defects in babies born to women who received dolutegravir for HIV.

Increasing Incidence of Syphilis in People With HIV

Increasing Incidence of Syphilis in People With HIV

By

Steady increases in the syphilis incidence rate occurred through 2015, particularly among people with HIV who are younger, non-Hispanic/Latino, and are men who have sex with men.

Truvada Approved for HIV-1 Pre-Exposure Prophylaxis in At-Risk Adolescents

Truvada Approved for HIV-1 Pre-Exposure Prophylaxis in At-Risk Adolescents

By

The use of Truvada for PrEP in the adolescent population was based on a single-arm, open-label clinical study (ATN113) among 67 HIV-1 negative young men (aged 15 to 17 years) who have sex with men (YMSM).

Importance of PrEP for People Involved in Criminal Justice Systems

Importance of PrEP for People Involved in Criminal Justice Systems

By

Important strategies to consider for people involved in the criminal justice systems include linkage to antiretroviral therapy for those who are HIV positive and linkage to PrEP postrelease and/or beginning PrEP before people are released so they build up adherence.

FDA Approves Epoetin Alfa Biosimilar Retacrit

FDA Approves Epoetin Alfa Biosimilar Retacrit

By

The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data which demonstrated a high degree of similarity between Retacrit and its reference product.

PD-1 Inhibitors Safe, Effective in Patients With HIV and Non-Small Cell Lung Cancer

PD-1 Inhibitors Safe, Effective in Patients With HIV and Non-Small Cell Lung Cancer

By

Nivolumab and pembrolizumab can be safe and effective for patients with NSCLC and HIV.

Women, HIV, and the Criminal Justice System: Prison Health Is Public Health

Women, HIV, and the Criminal Justice System: Prison Health Is Public Health

By

Jaimie P. Meyer, MD, from the Yale School of Medicine, discusses her work on identifying opportunities to reduce risk for HIV transmission, particularly in women involved in the criminal justice system.

Cancer Incidences and Burden Expected to Shift in HIV

Cancer Incidences and Burden Expected to Shift in HIV

The cancer burden among persons living with HIV is projected to shift by 2030.

Risk of Adverse Birth Outcomes in Women With HIV Using Tenofovir-Emtricitabine

Risk of Adverse Birth Outcomes in Women With HIV Using Tenofovir-Emtricitabine

By

The number of adverse birth outcomes was not higher with tenofovir, emtricitabine, and ritonavir-boosted lopinavir than with zidovudine, lamivudine, and ritonavir-boosted lopinavir or tenofovir, emtricitabine, and ritonavir-boosted atazanavir in HIV-infected women and their infants in the United States.

Eplerenone May Improve Cardiovascular Disease Risk in HIV

Eplerenone May Improve Cardiovascular Disease Risk in HIV

By

Researchers investigated effects of eplerenone on insulin sensitivity, inflammatory indices, and other metabolic parameters in HIV.

Increased Risk for Skin Cancer Among HIV-Infected Individuals

Increased Risk for Skin Cancer Among HIV-Infected Individuals

By

The risk for skin cancer was examined in patients with HIV infection.

<i>Legionella</i> Pneumonia Outcomes Similar in Adults With/Without HIV

Legionella Pneumonia Outcomes Similar in Adults With/Without HIV

By

Clinical presentation and outcomes in HIV-infected patients with Legionella pneumonia did not differ from patients without HIV infection.

Why Treating Major Depressive Disorder Improves Outcomes in HIV

Why Treating Major Depressive Disorder Improves Outcomes in HIV

By

Mental health problems are 1 of the most important reasons for failing to engage in long-term control of HIV.

In-utero exposure to tenofovir-emtricitabine not associated with higher risk of adverse birth outcomes

Pairwise comparisons of tenofovir-emtricitabine and ritonavir-boosted lopinavir (TDF-FTC-LPV/r), zidovudine-lamivudine and ritonavir-boosted lopinavir (ZDV-3TC-LPV/r), and tenofovir-emtricitabine and ritonavir-boosted atazanavir (TDF-FTC-ATV/r) HIV regimens among pregnant women with HIV showed all 3 regimens had comparable risks of preterm birth, low birth weight, and neonatal death.

Novel Antiretroviral Therapy Trogarzo Now Available to Treat HIV-1

Novel Antiretroviral Therapy Trogarzo Now Available to Treat HIV-1

By

The approval of Trogarzo was supported by a clinical trial (N=40) of heavily treatment-experienced adults with multidrug resistant HIV-1 infection who continued to have high levels of HIV RNA in their blood despite antiretroviral therapy.

HIV Primary Care Visit Intervals up to 9 Months Does Not Worsen Viral Load

HIV Primary Care Visit Intervals up to 9 Months Does Not Worsen Viral Load

By

Study showed very small changes in HIV viral load among patients who had gaps in primary care that exceeded 6 months but were less than 9 months in duration.

Cumulative Depression Increases Mortality in Women With HIV

Cumulative Depression Increases Mortality in Women With HIV

By

Findings highlight the clinical importance of enhanced treatment protocols designed to reduce the duration and frequency of depressive episodes in women living with HIV.

CDC: Many Adults Not Receiving Sexual Risk Assessments

CDC: Many Adults Not Receiving Sexual Risk Assessments

Less than half of women and a quarter of men with recent sexual activity receive sexual risk assessment.

Risk Factors for Measles Seronegativity in HIV

Risk Factors for Measles Seronegativity in HIV

Considering the resurgence of measles in Europe and the risk of severe complications associated with the infection, individuals with HIV born after 1970 or those who were vertically infected should be tested for measles-specific IgG, irrespective of ethnic background or migration status.

Non-Targeted HIV Testing in ED Acceptable to Patients

Non-Targeted HIV Testing in ED Acceptable to Patients

A non-targeted testing approached revealed a high HIV prevalence with a significant burden of undiagnosed HIV infection in the emergency department.

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection

By

Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.

How San Francisco Is Tackling the HIV/HCV and Opioid Epidemics

How San Francisco Is Tackling the HIV/HCV and Opioid Epidemics

By

Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.

Novel Digital ELISA May Detect, Quantify Low HIV p24 Concentrations in CSF

Novel Digital ELISA May Detect, Quantify Low HIV p24 Concentrations in CSF

By

More comprehensive research will be needed to further investigate cerebrospinal fluid p24 by high-sensitivity assay as a marker for neurocognitive impairment during poorly controlled HIV and as a marker for HIV central nervous system reactivation during latency reversal therapy.

Generic HIV Medicines: Boon or Bust?

Generic HIV Medicines: Boon or Bust?

By

Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.

Age, Exposure to Antiretrovirals Affect Diabetes Risk in HIV

Age, Exposure to Antiretrovirals Affect Diabetes Risk in HIV

By

Interventions for diabetes prevention and management may be needed to reduce the risk for diabetes in patients with HIV.

About Half of Pregnant Women With HIV Have C-Sections

About Half of Pregnant Women With HIV Have C-Sections

About half of pregnant women with HIV infection underwent cesarean delivery between 1998 and 2013.

Antifungal Combination Treatment for Cryptococcal Meningitis in HIV

Antifungal Combination Treatment for Cryptococcal Meningitis in HIV

By

The absence of availability of amphotericin B or in conditions in which amphotericin B cannot be administered safely, the oral combination of fluconazole plus flucytosine provides an effective and sustainable alternative.

Sign Up for Free e-newsletters